Hypofractionated stereotactic body radiotherapy for localized prostate cancer – first Nordic clinical experience

Figures & data

Table 1. Dose–volume constraints for treatment planning.

Prostate	V (35 or 36.25 Gy) ≥ 99%
PTV	V (35 or 36.25 Gy) ≥ 95%
Rectum	max dose 38 Gy
	V (36.00 Gy) < 1 cc
	V(25.00 Gy) < 20 cc
	V(36.25 Gy) < 5%
	V (32.63 Gy) < 10%
	V (29.00 Gy) < 20%
	V (18.13 Gy) < 50%
Bowel	V (25.00 Gy) < 1 cc
Bladder	max dose 38 Gy
	V (37.50 Gy) < 5 cc
	V (37.00 Gy) < 10 cc
Bladder wall	V(18.30 Gy) < 15 cc
Urethra	max dose 40 Gy

Figure 1. Flow chart of the patients eligible for the final analysis.

Table 2. Patient demographics.

cT stage	Patients, n	%
T1a-c	116	53.2
T2a-b	13	6.0
T2c	18	8.3
T3-4	70	32.1
NA	1	0.4
Gleason score
≤6	107	49.1
7	82	37.6
≥8	29	13.3
Initial PSA (ng/ml)
PSA ≤10	109	50.0
PSA 10–20	75	34.4
PSA >20	32	14.7
NA	2	0.9
Risk group^a
Low	48	22.0
Intermediate	59	27.1
High	111	50.9
ADT
No	76	34.9
Yes	142	65.1
Risk group^b
Low	14	29.2
Intermediate	30	50.8
High	98	88.3
Duration of ADT
≤7 mo	59	41.5
12–18 mo	15	10.6
≥24 mo	56	39.4
NA	12	8.5

^a D’Amico risk stratification. mo: months; NA: not available.

^bPatients receiving ADT.

Figure 2. Decline of the median PSA over time in different treatment groups.

Figure 3. Decline of the median PSA over time in different risk-groups.